NovoCure downgraded by H.C. Wainwright with a new price target
$NVCR
Medical/Dental Instruments
Health Care
H.C. Wainwright downgraded NovoCure from Buy to Neutral and set a new price target of $25.00 from $85.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | $24.00 → $30.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2023 | $15.00 | Neutral | JP Morgan |
| 8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright |
| 8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler |
| 8/4/2023 | $51.00 | Outperform | SVB Securities |
| 7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI |
| 6/7/2023 | $53.00 → $46.00 | Underperform → Neutral | Wedbush |
| 5/16/2023 | $70.00 → $104.00 | Equal Weight → Overweight | Wells Fargo |
Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
8-K - NovoCure Ltd (0001645113) (Filer)
10-Q - NovoCure Ltd (0001645113) (Filer)
8-K - NovoCure Ltd (0001645113) (Filer)
H.C. Wainwright upgraded NovoCure from Neutral to Buy and set a new price target of $30.00 from $24.00 previously
JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00
H.C. Wainwright downgraded NovoCure from Buy to Neutral and set a new price target of $25.00 from $85.00 previously
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 Novocure (NASDAQ:NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative thera
Novocure (NASDAQ:NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three-month quarter and first nine months of the year that ended September 30, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations p
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "The second quarter was a period of consistent execution at Novocure," said Asaf Danziger, Novocure's Chief Executive Officer. "We began the year with three k
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $2
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a In-Line and raises the price target from $14.5 to $20.
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
Novocure (NASDAQ:NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas. Novocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in mouse studies as well as research identifying the optimal positioning of its newly approved Head Flexible Electrodes (HFE) transducer arrays for infratentorial brain tumors. Novocure will also present a new subgroup analysis of patients from the xCures real-world data platform that assesses the results of
New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ:NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM). Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells. Th
Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product